Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KDM6B | O15054 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12019810 | 0.81 | ALDH1A1 (0.50) | ALDH1A1TDP1 | |
| SCHEMBL1492543 | 0.81 | ALDH1A1 (0.50) | ALDH1A1TDP1 | |
| SCHEMBL7305569 | 0.78 | SOAT1 (0.33) | KDM4E | |
| SCHEMBL19014327 | 0.77 | TDP1 (0.41) | TDP1 | |
| SCHEMBL23009650 | 0.76 | — | — | |
| SCHEMBL110123 | 0.74 | ALDH1A1 (0.60) | ALDH1A1TDP1KDM4EKDM6BKDM5C | |
| SCHEMBL23009484 | 0.74 | — | — | |
| SCHEMBL25635640 | 0.73 | ALDH1A1 (0.40) | ALDH1A1TDP1KDM4EKDM6BKDM5C | |
| SCHEMBL6874101 | 0.72 | KDM4E (0.35) | ALDH1A1TDP1KDM4EKDM6BKDM5C | |
| SCHEMBL1902452 | 0.72 | SLC22A6 (0.39) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11680060-B2 | Bicycloheptane pyrrolidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680060-B2 | Bicycloheptane pyrrolidine orexin receptor agonists | HCRTR1, HCRTR2, CRHR1 | ALDH1A1 1885/4885TDP1 4317/4885KDM4E 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.